Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - UNIGENE LABORATORIES INCex99-1.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):
November 20, 2012
 

Unigene Laboratories, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
0-16005
 
22-2328609
(State or other jurisdiction of
incorporation or organization)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
         
81 Fulton Street, Boonton, New Jersey
 
07005
(Address of principal executive offices)
 
(Zip Code)
 
(973) 265-1100
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
o
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
o
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
o
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 

 
 
Section 8 – Other Events

 
Item 8.01. Other Events.
 
On November 20, 2012, Unigene Laboratories, Inc. issued a press release announcing a general corporate update and an update to the Company’s financial condition.  A copy of the press release is furnished as Exhibit 99.1 to this report.





 
Section 9 – Financial Statements and Exhibits
 

 
 
Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.
Document Description
99.1
Press Release dated November 20, 2012
   
 
 
 

 
 
Signatures
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
UNIGENE LABORATORIES, INC.
 
     
       
 
By:
/s/ Gregory T. Mayes
 
    Gregory T. Mayes, President and General Counsel  
       
       
 
 
Date:        November 20, 2012
 
 
 

 

 
Exhibit Index

Exhibit No.
Document Description
99.1
Press Release dated November 20, 2012